Tamsulosin Hydrochloride
Product Images NDC 16590-298

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 16590-298). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Tamsulosin HCl Label 298)

TAMSULOSIN HYDROCHLORIDE 0.4 mg capsule label from STAT RX USA LLC. The label indicates 30 capsules per package and specifies it is a generic for Tamsulosin. Manufacturer is Wockhardt USA LLC, Parsippany, NJ. The label includes the NDC number 16590-298-30 and dosing/storage instructions.*

FDA Label Image

Figure1 (Tamsulosin HCl Capsules Figure 1)

A line graph showing plasma concentration (ng/mL) over time (hours) comparing fasted and fed states. The graph includes two curves: a dashed line for fasted condition that peaks sharply around 4 hours, and a solid line for fed condition with a lower, more gradual peak. Both lines decline towards baseline by 36 hours.*

FDA Label Image

Figure 2a (Tamsulosin HCl Capsules Figure 2a)

A line graph showing mean change versus duration of treatment in weeks for TAMSULOSIN HYDROCHLORIDE clinical data. The graph compares treatment groups with doses 0.8 mg and 0.4 mg against placebo, illustrating the mean change over a period up to 13 weeks with participant counts at each time point.*

FDA Label Image

Figure 2b (Tamsulosin HCl Capsules Figure 2b)

A line graph showing mean change over treatment duration in weeks for three groups: 0.3 mg dose, 0.4 mg dose, and placebo. The x-axis represents weeks of treatment up to 13 weeks and last observation carried forward (LOCF), while the y-axis shows mean change values from 0 to -11. The 0.3 mg and 0.4 mg treatment groups show greater mean change reductions compared to placebo, which remains near -3.*

FDA Label Image

Figure3a (Tamsulosin HCl Capsules Figure 3a)

A line graph showing the mean change in mL/sec over a duration of 13 weeks for TAMSULOSIN HYDROCHLORIDE 0.8 mg, 0.4 mg, and placebo groups. The x-axis represents weeks of treatment, and the y-axis measures mean change in flow rate. Two treatment groups show a higher and sustained increase compared to placebo throughout the study.*

FDA Label Image

Figure3b (Tamsulosin HCl Capsules Figure 3b)

A line graph depicting the mean change in milliliters per second over the duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.8 mg, 0.4 mg, and placebo. The graph includes data points from baseline to approximately 13 weeks and a last observation carried forward (LOCF) category, with sample sizes varying at each time point for all three groups.*

FDA Label Image

Structure (Tamsulosin HCl Capsules Structure)

Chemical structure of Tamsulosin Hydrochloride showing aromatic rings and functional groups including sulfonamide, methoxy, and ethoxy substituents, consistent with the active ingredient in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.